

# Continuing Education Credit Information

## Course Description

This biennial, multidisciplinary, one-day conference will provide an update on the clinical management of patients with kidney and bladder (urothelial) cancers. Didactic lectures will present the many recent advances in the treatment of these diseases and their integration into the multidisciplinary management of patients with early stage, high risk and metastatic disease. Presentations will also discuss emerging controversies and ongoing research aimed at addressing them. Interactive discussions with experts in the field will enhance the learning experience.

## Learning Objectives

- Discuss current status of adjuvant therapy for patients with high risk kidney cancer
- Analyze treatment options for second line therapy for immune therapy resistant kidney cancer
- Evaluate the role of immune therapy alone and in combination for patients with kidney cancer
- Discuss the current approaches to treatment of patients with non clear cell kidney cancer
- Evaluate the changing role of VEGF therapy in patients with kidney cancer
- Analyze current unresolved clinical management issues and clinical research opportunities
- Evaluate the role of surgery in the management of patients with all stages of kidney cancer
- Describe the evaluation and management of BCG refractory non-muscle invasive bladder cancer
- Evaluate molecular advances in urothelial carcinoma that support personalized bladder cancer management strategies
- Describe the evolution of immunotherapy in the treatment of advanced urothelial cancer
- Utilize appropriate multidisciplinary therapy approaches for muscle invasive bladder cancer
- Analyze critical clinical questions in urothelial carcinoma that are being addressed by clinical research

## Target Audience

This conference is intended for oncologists, pathologists, radiation oncologists, urologists, residents, fellows, medical students, nurse practitioners, nurses, physician assistants, pharmacists, allied health professionals, and other members of the healthcare team interested in the management of kidney and bladder cancers.

## Accreditation



In support of improving patient care, MedStar Health is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), the American Nurses Credentialing Center (ANCC) and the American Academy of PAs (AAPA) to provide continuing education for the healthcare team.



This activity was planned by and for the healthcare team, and learners will receive 7 Interprofessional Continuing Education (IPCE) credits for learning and change.

# Kidney and Bladder Cancers: Updates on Clinical Management

March 23, 2019 | Bethesda North Marriott Hotel & Conference Center | Rockville, MD

MedStar Health  
3007 Tilden St., NW, Suite 3N  
Washington, DC 20008



For more information and to register, please visit  
[CE.MedStarHealth.org/KBC](http://CE.MedStarHealth.org/KBC)

# Kidney and Bladder Cancers: Updates on Clinical Management

# 2019



## March 23, 2019

Bethesda North Marriott Hotel & Conference Center | Rockville, MD

### Course Co-Directors:

**Michael B. Atkins, MD**  
Georgetown Lombardi Comprehensive Cancer Center  
MedStar Georgetown University Hospital  
MedStar Georgetown Cancer Institute  
Washington, D.C.

**Keith J. Kowalczyk, MD**  
MedStar Georgetown University Hospital  
MedStar Washington Hospital Center  
Washington, D.C.

**George K. Phillips, MBBS, MD, MPH**  
Georgetown Lombardi Comprehensive Cancer Center  
MedStar Georgetown University Hospital  
MedStar Washington Hospital Center  
Washington, D.C.

**Lambros Stamatakis, MD**  
MedStar Georgetown University Hospital  
MedStar Washington Hospital Center  
Washington Cancer Institute  
Washington, D.C.



Course Co-Directors

**Michael B. Atkins, MD**  
Deputy Director, Georgetown Lombardi Comprehensive Cancer Center  
William M. Scholl Professor and Vice-Chair Department of Oncology  
Georgetown University Medical Center  
Staff Physician, Division of Hematology/Oncology  
MedStar Georgetown University Hospital  
Head, Kidney Cancer Section – Genitourinary Disease Group  
MedStar Georgetown Cancer Institute  
Washington, D.C.

**Keith J. Kowalczyk, MD**  
Co-Director, Urologic Oncology  
MedStar Georgetown University Hospital  
MedStar Washington Hospital Center  
Associate Professor, Urology  
Georgetown University School of Medicine  
Washington, D.C.

Faculty

**KEYNOTE SPEAKER**  
**James M. McKiernan, MD**  
John K. Lattimer Professor and Chairman, Urology  
Urologist-in-Chief  
New York–Presbyterian Hospital  
New York, NY

**Piyush K. Agarwal, MD**  
Head, Bladder Cancer Section  
Urologic Oncology Branch  
National Cancer Institute  
National Institutes of Health  
Bethesda, MD

**Andrea B. Apolo, MD**  
Chief, Bladder Cancer Section Genitourinary Malignancies Branch  
National Cancer Institute  
National Institutes of Health  
Bethesda, MD

**Gennady Bratslavsky, MD**  
Chair, Urology  
Deputy Director, Upstate Cancer Center  
SUNY Upstate Medical University  
Syracuse, NY

**Jason A. Efstathiou, MD, DPhil**  
Director, Genitourinary Division  
Department of Radiation Oncology  
Clinical Co-Director, The Claire and John Bertucci Center for  
Genitourinary Cancers  
Massachusetts General Hospital  
Boston, MA

**Alvin C. Goh, MD**  
Director, Robotic Urologic Surgery Technology and Education  
Urology Service, Surgery  
Memorial Sloan Kettering Cancer Center  
New York, NY

**George K. Philips, MBBS, MD, MPH**  
Staff Physician, Hematology/Oncology  
MedStar Georgetown University Hospital  
MedStar Washington Hospital Center  
Georgetown Lombardi Comprehensive Cancer Center  
Professor and Vice Chair, Medicine  
Georgetown University School of Medicine  
Washington, D.C.

**Lambros Stamatakis, MD**  
Co-Director, Urologic Oncology  
MedStar Georgetown University Hospital  
MedStar Washington Hospital Center  
Washington Cancer Institute  
Assistant Professor, Urology  
Georgetown University School of Medicine  
Washington, D.C.

**Jean H. Hoffman-Censits, MD**  
Medical Oncologist, Genitourinary Oncology  
The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins  
Johns Hopkins Greenberg Bladder Cancer Institute  
Baltimore, MD

**Alexander Kutikov, MD**  
Chief, Division of Urology and Urologic Oncology  
Fox Chase Cancer Center  
Temple Health  
Philadelphia, PA

**David F. McDermott, MD**  
Director, Cutaneous and Immuno-Oncology Programs  
Beth Israel Deaconess Medical Center  
Leader, Kidney Cancer Program  
Dana-Farber Harvard Cancer Center  
Boston, MA

**Elizabeth R. Plimack, MD, MS**  
Chief, Division of Genitourinary Medical Oncology  
Director, Genitourinary Clinical Research  
Fox Chase Cancer Center  
Temple Health  
Philadelphia, PA

**David I. Quinn, MBBS, PhD**  
Medical Director  
Norris Cancer Hospital  
Section Head, Genitourinary Oncology  
Division of Oncology in the Department of Medicine  
University of Southern California  
Los Angeles, CA

**Nizar M. Tannir, MD**  
Deputy Chair, Genitourinary Medical Oncology  
Division of Cancer Medicine  
The University of Texas MD Anderson Cancer Center  
Houston, TX

Agenda

**7:00 a.m.** Registration and Continental Breakfast

**7:50 a.m.** Welcome and Introduction  
Michael B. Atkins, MD

**SESSION I: Kidney Cancer**  
Moderators: Michael B. Atkins, MD; Keith J. Kowalczyk, MD

**8:00 a.m.** Diagnosis, Prognosis, and Management of Small Renal Masses  
Alexander Kutikov, MD

**8:20 a.m.** Current Status of Anti-VEGF Therapies in RCC  
Elizabeth R. Plimack, MD, MS

**8:40 a.m.** Role of Immunotherapy and IO Combinations in RCC  
Michael B. Atkins, MD

**9:00 a.m.** Role of Biomarkers in Choosing ccRCC Therapy  
David F. McDermott, MD

**9:20 a.m.** Update on Cytooreductive Nephrectomy: Implication in the Age of CARMENA and Immunotherapy  
Gennady Bratslavsky, MD

**9:40 a.m.** Treatment of Non-Clear Cell RCC  
Nizar M. Tannir, MD

**10:00 a.m.** Break and Visit Exhibits

**10:15 a.m.** Current Status of and Controversies in Adjuvant/Neoadjuvant Rx  
David I. Quinn, MBBS, PhD

**10:35 a.m.** Case Presentations and Panel Discussion  
Moderators: Michael B. Atkins, MD; Keith J. Kowalczyk, MD  
Panelists: G. Bratslavsky, A. Kutikov, D. McDermott, E. Plimack, D. Quinn, N. Tannir

**SESSION II: Bladder Cancer**  
Moderators: George K. Philips, MBBS, MD, MPH; Lambros Stamatakis, MD

**11:15 a.m.** KEYNOTE LECTURE  
Controversies in the Management of Favorable Outcomes after Neoadjuvant Chemotherapy for Muscle Invasive Bladder Cancer  
James M. McKiernan, MD

**12:00 p.m.** Lunch and Visit the Exhibits

**1:00 p.m.** Update on Non-Muscle Invasive Bladder Cancer: What’s New?  
Lambros Stamatakis, MD

**1:20 p.m.** Interpretation of Genomic Data for Bladder Cancer and Clinical Impact  
Piyush K. Agarwal, MD

**1:40 p.m.** Questions and Discussion  
Moderator: George K. Philips, MBBS, MD, MPH  
Panelists: P. Agarwal, L. Stamatakis

**2:00 p.m.** State-of-the Art: Minimally Invasive Cystectomy and Intracorporeal Urinary Diversion for Muscle Invasive Bladder Cancer  
Alvin C. Goh, MD

**2:20 p.m.** Advances in Bladder-Sparing Trimodality Therapy for Muscle-Invasive Bladder Cancer  
Jason A. Efstathiou, MD, DPhil

**2:45 p.m.** Updates on Perioperative Chemotherapy and Immunotherapy  
Andrea B. Apolo, MD

**3:10 p.m.** Metastatic Bladder Cancer: Improving Outcomes and Clinical Trials  
Jean H. Hoffman-Censits, MD

**3:30 p.m.** Case Presentations  
George K. Philips, MBBS, MD, MPH; Lambros Stamatakis, MD

**3:50 p.m.** Closing Remarks  
Lambros Stamatakis, MD

**4:00 p.m.** Adjourn

Registration Information

Registration Fees

Physician	\$150
Resident and Fellow	\$50
Physician Assistant	\$50
Nurse Practitioner	\$50
Nurse	\$50
Allied Health Professional	\$50
Pharmacist	\$50

Online Registration Preferred

Please visit our secure website at **CE.MedStarHealth.org/KBC** for updated program and registration information. We are unable to accept registrations or cancellations by telephone. If you wish to pay your registration fee by check, please download and print a registration form and mail it to the address on the registration form with your check.

All registrations will be confirmed by email only. Please use an email address that you check regularly. If you have questions regarding registration or do not receive an email confirmation of your registration within 1-2 business days, please contact us at **MedStarCME@gmail.com** or **202-780-1655**.

Cancellation Policy

Cancellations made in writing by **February 8, 2019** will be subject to a 50% penalty. No refunds will be given after **February 8, 2019**. Cancellations will not be accepted by telephone. In the unlikely event that the course is canceled, MedStar Health will refund the registration fee, but is not responsible for any travel costs.

Please call **202-780-1655** or email **MedStarCME@gmail.com** if you have any questions or need any additional information.

Venue Information

Bethesda North Marriott Hotel & Conference Center

5701 Marinelli Rd. | Rockville, MD 20852

Special Assistance

MedStar Health wishes to ensure that no individual with a disability is excluded, denied services, segregated or otherwise treated differently from other individuals because of the absence of auxiliary aids or services identified in the Americans with Disabilities Act. Please contact **202-780-1655** to notify us of your needs.